Alnylam stock price target raised to $535 from $459 by Truist Securities

Investing.com - Truist Securities has raised its price target on Alnylam Pharmaceuticals (NASDAQ:ALNY) to $535 from $459 while maintaining a Buy rating, citing increased third-quarter Amvuttra sales projections. According to InvestingPro data, analyst targets for ALNY currently range from $35 to $75, with a Strong Buy consensus rating of 1.4 (where 1 is Strong Buy and 5 is Strong Sell).

The firm expects Alnylam to deliver "another strong beat & raise" for Q3 2025, with analyst estimates suggesting Amvuttra U.S. sales could reach approximately $550 million based on prescription data. Despite the anticipated positive reaction to earnings, Truist notes risk/reward may be "negatively skewed" given the stock’s significant outperformance this year.

Truist’s biotech sector review highlights strong performance across the industry during the third quarter, with the XBI biotech index gaining 32% since the end of Q2. The firm maintains that "biotech is...back!?" with seven of its 13 covered companies significantly outperforming the sector benchmark. InvestingPro subscribers can access over 10 additional exclusive insights about Alnylam’s financial health, which currently rates as "FAIR" with a score of 2.39 out of 5.

Among commercial-stage companies in Truist’s coverage, Alnylam shares have risen 49% since its Q2 earnings report, compared to the XBI’s 30% gain. The firm also previewed earnings for other biotech companies including Argenx (NASDAQ:ARGX), BridgeBio (NASDAQ:BBIO), Biogen (NASDAQ:BIIB), Harmony Biosciences (NASDAQ:HRMY), and Neurocrine Biosciences (NASDAQ:NBIX).

Development-stage companies showed particularly strong performance, with Truist noting that five of seven outperformed the XBI index, including Pyxis Oncology (NASDAQ:PVLA), which was described as "the clear winner" across its coverage universe due to increased investor awareness and upcoming data catalysts.

In other recent news, Upstream Bio has been the focus of several analyst reports highlighting its potential in the biopharmaceutical sector. Truist Securities initiated coverage on the company with a Buy rating and a $47.00 price target, emphasizing the potential of its TSLP-receptor inhibitor, verekitug, as a promising treatment for respiratory diseases. Piper Sandler reiterated an Overweight rating with a $75.00 price target, noting the company’s positive momentum following its IPO. The firm maintained its optimistic outlook despite initial stock fluctuations. Additionally, JPMorgan reiterated its Overweight rating with a $35.00 price target, anticipating positive results from upcoming clinical trials. These developments underscore the growing interest in Upstream Bio’s innovative treatment options and its position in the market.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.